New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 18, 2014
18:04 EDTABBV, SHPGAbbVie purchase of Shire worth the premium, Barron's reports
AbbVie (ABBV) did not get a bargain when it purchased Shire (SHPG). However, the deal will go a long way towards lowering AbbVie's tax burden and enlarging its portfolio, which should drive the stock price higher over the long term, Barron's reports. Reference Link
News For ABBV;SHPG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 25, 2015
19:34 EDTABBVExperts tell White House to expand use of Hepatitis C drugs, NYT says
Health care experts from the Public Health Service and the Advisory Council on H.I.V./AIDS have recommended that Medicaid officials expand the use of costly Hepatitis C drugs including AbbVie's (ABBV) Viekira Pak and Gilead's (GILD) Sovaldi and Harvoni, reports the New York Times, citing correspondence sent to the White House. The advisory council said current usage limitations on the drugs are "unreasonable," but it also suggested that manufacturers disclose drug development costs in the face of the significant price tags on modern Hepatitis C treatments. Reference Link
16:43 EDTSHPGOn The Fly: Top stock stories for Tuesday
Subscribe for More Information
09:03 EDTABBV, SHPGAcorda has major overhang removed by IPR denials, says Leerink
Subscribe for More Information
07:06 EDTSHPGShire reaches CINRYZE agreement with Sanquin Blood Supply
Subscribe for More Information
August 24, 2015
18:55 EDTSHPGOn The Fly: After Hours Movers
Subscribe for More Information
18:52 EDTSHPGJazz, Celgene, Shire up after USPTO rejects Acorda patent challenge
Subscribe for More Information
August 21, 2015
09:38 EDTSHPGUBS global healthcare analysts hold an analyst/industry conference call
Subscribe for More Information
August 19, 2015
06:09 EDTABBVUnited Therapeutics agrees to sell PPRV to AbbVie for $350M
United Therapeutics (UTHR) announced that it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher, or PPRV, to a subsidiary of AbbVie (ABBV). United Therapeutics received the PPRV when Unituxin was approved by the FDA for the treatment of neuroblastoma, a rare pediatric disease. Upon closing of the transaction, United Therapeutics will receive $350M in cash in exchange for the PPRV. The voucher was awarded by the FDA under a provision that encourages development of new drugs and biologics for the prevention and treatment of rare pediatric diseases.
05:57 EDTABBVAbbVie implied volatility of 20 at lower end of index mean range
August 17, 2015
06:55 EDTSHPGBaxalta initiated with an Outperform at William Blair
Subscribe for More Information
06:48 EDTSHPGShire to raise Baxalta offer if given access to company's books, Telegraph says
Subscribe for More Information
August 16, 2015
15:03 EDTSHPGShire must raise bid to $35B to interest Baxalta, Sunday Times says
Shire (SHPG) will have to increase its bid for Baxalta (BXLT) by about $5B to $35B in order to entice the company's board, reports the Sunday Times, citing people working on the deal. Even a $35B deal would only be a starting point, cautioned the sources. Reference Link
August 14, 2015
17:08 EDTSHPGPaulson & Co gives quarterly update on stakes
Subscribe for More Information
07:15 EDTSHPGShire eyes more details of Baxalta sales outlook, Bloomberg reports
Subscribe for More Information
August 13, 2015
10:02 EDTSHPGMajor Shire holders comfortable with $50 per share Baxalta bid, Reuters says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use